Melanocortin Agonists / PT-141
Bremelanotide (PT-141)
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Approved for premenopausal female HSDD (Vyleesi, 2019); not approved for male ED
Reference only. Not medical advice.
What can go wrong
Nausea (common), flushing, headache, and transient blood-pressure increase; focal hyperpigmentation with repeated use. Gray-market peptide products lack purity and dosing assurance. Use for male ED is off-label and not FDA-evaluated for that purpose.
This is something to take to a clinician. The Atlas can tell you what is known about melanocortin agonists / pt-141 in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Bremelanotide (PT-141) is a melanocortin receptor agonist that acts centrally on the nervous system to drive sexual arousal, unlike the peripheral vascular action of PDE5 inhibitors. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, but not for male ED. Early male ED studies showed promise; it is now widely sold through gray-market peptide vendors and some telehealth channels for men, outside its approved indication.
A brain-level arousal pathway, and a gray-market peptide for men.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
PT-141 activates central melanocortin receptors (notably MC4R) in the hypothalamus, stimulating sexual arousal and erection through a neural pathway distinct from the peripheral nitric-oxide/cGMP mechanism of PDE5 inhibitors, meaning it can act on desire as well as erection.
What people get wrong
Often saidPT-141 is an FDA-approved men's ED drug
ActuallyIt is approved only for female HSDD. Its use in men is off-label, and most male supply is gray-market peptide of uncertain quality.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Approved as
- Vyleesi (female HSDD), 2019
- Male ED status
- Not approved
- Mechanism
- Central (CNS), not vascular
- Route
- Subcutaneous injection / nasal
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Melanocortin Agonists / PT-141. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.